Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ·Healthcare·Biotechnology
$231.68
-4.18%
Mkt Cap $4.61B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 26, 2026 | $55.59M | $59.67M | +7.33% | $1.46 | $2.02 | +38.36% | — | — |
| Q4 2025 Nov 6, 2025 | $55.59M | $115.46M | +107.71% | $1.97 | $3.09 | +56.85% | — | — |
| Q3 2025 Aug 7, 2025 | $52.83M | $47.63M | -9.85% | $1.54 | $1.60 | +3.90% | — | — |
| Q2 2025 May 8, 2025 | $44.30M | $45.33M | +2.32% | $1.30 | $1.33 | +2.31% | — | — |
| Q1 2025 Feb 27, 2025 | $35.31M | $42.81M | +21.26% | $1.37 | -$1.64 | -219.71% | — | — |
| Q4 2024 Nov 7, 2024 | $39.01M | $51.81M | +32.81% | $0.75 | -$0.39 | -152.00% | — | — |
| Q3 2024 Aug 6, 2024 | $32.86M | $41.53M | +26.39% | $1.10 | $1.40 | +27.27% | — | — |
| Q2 2024 May 7, 2024 | $27.92M | $30.98M | +10.95% | $1.13 | $1.20 | +6.19% | — | — |
| Q1 2024 Feb 27, 2024 | $25.72M | $28.10M | +9.26% | $0.58 | $1.05 | +81.03% | — | — |
| Q4 2023 Nov 8, 2023 | $27.19M | $32.87M | +20.88% | $0.68 | $1.02 | +50.00% | — | — |
| Q3 2023 Aug 8, 2023 | $25.73M | $26.37M | +2.47% | $0.76 | $1.42 | +86.84% | — | — |
| Q2 2023 May 4, 2023 | $34.04M | $43.98M | +29.20% | $0.89 | $2.28 | +156.18% | — | — |
| Q1 2023 Feb 22, 2023 | $44.09M | $50.38M | +14.27% | $1.23 | $1.36 | +10.57% | — | — |
| Q4 2022 Nov 7, 2022 | $38.32M | $66.09M | +72.45% | $0.45 | $0.41 | -8.89% | — | — |
| Q3 2022 Aug 8, 2022 | $37.73M | $57.42M | +52.16% | $0.54 | $0.34 | -37.04% | — | — |
| Q2 2022 May 4, 2022 | $34.21M | $45.69M | +33.57% | $0.61 | $0.58 | -4.92% | — | — |
| Q1 2022 Feb 17, 2022 | $65.09M | $72.47M | +11.35% | $1.38 | $1.80 | +30.43% | — | — |
| Q4 2021 Nov 9, 2021 | $53.27M | $64.83M | +21.71% | $1.02 | $1.58 | +54.90% | — | — |
| Q3 2021 Jul 29, 2021 | $70.49M | $84.67M | +20.12% | $1.36 | $1.63 | +19.85% | — | — |
| Q2 2021 May 3, 2021 | $63.00M | $55.15M | -12.46% | $1.13 | $1.41 | +24.78% | — | — |